A variant of tissue plasminogen activator (t-PA) comprised of the Kringle 2 and the protease domain shows a significant difference in the in vitro rate of plasmin formation as compared to the recombinant human t-PA from transformed chinese hamster ovary cells

Fibrinolysis and Proteolysis

Volumn 7, Issue 6, 1993, Pages 365-372

  Kohnert, U ^a   Horsch, B ^a   Fischer, S ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRIN DEGRADATION PRODUCT; FIBRINOLYTIC AGENT; RETEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CHO CELL; CONTROLLED STUDY; FIBRINOLYSIS; NONHUMAN;

EID: 0027507724     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/0268-9499(93)90060-9     Document Type: Article

References (18)

1. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022
2. On the interaction of the finger and the kringle 2 domain of tissuetype plasminogen activator with fibrin
3. Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis
4. Kinetics of the tissue-type plasminogen activator mediated activation of plasminogen. The influence of CNBr fibrin(ogen) fragment FCB-2 and different forms of plasminogen
5. Kinetics of the activation of plasminoigen by human tissue plasminogen activator
6. Studies of the kinetics of plasminogen activation by tissue plasminogen activator
7. Comparison of the kinetic parameters of the activation of glu-plasminogen by tissue plasminogen activators obtained from various sources
8. Human tissue-type plasminogen activator
9. Binding of fibrin fragments to one-chain and two-chain tissue-type plasminogen activator
10. Purification of rat fibrinogen and its constituent chains
11. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma
12. A rapid and sensitive method for the quanitification of microgram quantities of protein utilizing the principle of protein-dye binding
13. Evaluation of thrombolytic and systemic effects of the novel plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis
14. Pharmacokinetics and effects on the hemostatic system of bolus application of a novel recombinant plasminogen activator in AMI patients
15. Klinische and biochemische Zielsetzung bei der Thrombolysetherapie mit Neothrombolytika
16. Kinetic characterisation of tissue-type plasminogen activator (t-PA) and t-PA deletion variants